Humble Bee Bio is on a mission to create a biodegradable alternative to plastics by synthesizing the biology of bees. TechCrunch reports: While the New Zealand-based company is still at an early stage -- it's about halfway through its proof of concept -- if Humble Bee is successful, its bioplastics are likely to make it into the sustainable textiles industry. Humble Bee, which just raised $3.2 million (NZD $5 million) in convertible notes as part of its Series A, has been studying the Australian masked bee, a type of solitary bee that doesn't make honey, but does make a nesting material for laying larvae in, which has many plastic-like properties. "It's resistant to acids and bases. It's hydrophobic, it's waterproof, it's flame retardant, it's stable up to 240 degrees Celsius," Ryan Graves, Humble Bee's chief technology officer, told TechCrunch. "The idea is, how do we recreate this?"

The team is using a synthetic biology approach that involves going into the bee's genetic code and identifying the genes and proteins responsible for the nesting material. Humble Bee has extracted the code and is trying to recreate it in the laboratory. Next, the company will attempt to synthesize plastic-like materials, focusing on four different types of biomaterials that can be turned into fibers and finishing for fabrics. Humble Bee is aiming for anywhere from March to June 2023 to prove out the concept, at which point the team hopes to scale production using industrial-scale fermentation. "There's a degree of exploration still to go on," said Graves, "The processes are time-intensive and they are challenging. Getting going from code to protein is usually a 12-month process, and then we need to scale it up to get hundreds of grams of the stuff out."

An anonymous reader quotes a report from The Guardian: The building of the world's largest bioreactors to produce cultivated meat has been announced, with the potential to supply tens of thousands of shops and restaurants. Experts said the move could be a "gamechanger" for the nascent industry. The US company Good Meat said the bioreactors would grow more than 13,000 tons of chicken and beef a year. It will use cells taken from cell banks or eggs, so the meat will not require the slaughter of any livestock. There are about 170 companies around the world working on cultured meat, but Good Meat is the only company to have gained regulatory approval to sell its product to the public. It began serving cultivated chicken in Singapore in December 2020.

The creation of Good Meat's 10 new bioreactors is under way, the company says, each of which has a capacity of 250,000 liters and will stand four stories tall, far bigger than any constructed to date. The US site for the facility is due to be finalized within three months and operational in late 2024, reaching 11,800 tons a year by 2026 and 13,700 tons by 2030. The bioreactors are being manufactured as part of an agreement with ABEC, a leading bioprocess equipment manufacturer, which is also making a 6,000-liter bioreactor for Good Meat's Singapore site -- this is scheduled to begin production in early 2023 and will itself be the biggest cultured meat bioreactor installed to date. Cultivated meat has not yet been approved for sale by the US Food and Drug Administration. "Weâ(TM)ve submitted our application," said Josh Tetrick, the chief executive of Good Meatâ(TM)s parent company, Eat Just. "Weâ(TM)ve found the agency to be fully engaged, asking all the questions youâ(TM)d expect, from cell identification to final product. Weâ(TM)d prefer not to try to predict if and when [approval] will occur."

Tetrick also said the company had produced a cell growth serum that does not require the use of bovine fetuses, which were previously widely used.

An anonymous reader quotes a report from The Guardian: Scientists have created genetically edited tomatoes, each containing as much provitamin D3 -- the precursor to vitamin D -- as two eggs or a tablespoon of tuna. Outdoor field trials of the tomatoes are expected to begin in the UK next month, and if successful, could provide an important new dietary source of vitamin D. The tomato plants were created by making tiny changes to an existing tomato gene using an editing technique called Crispr-Cas9. "It's like a pair of molecular tweezers, which you can use to precisely snip out a very small fragment of the gene to enhance a desirable trait in plants a lot quicker than traditional breeding process, and without introducing any foreign DNA from other species," said Jie Li at the John Innes Centre in Norwich, who led the research.

In this case, their focus was an enzyme found in tomato plants that normally converts provitamin D3 into cholesterol. By altering this enzyme, the researchers managed to block this pathway, meaning provitamin D3 accumulated in the tomatoes' fruits and leaves. They calculated that the amount of provitamin D3 in one tomato fruit -- if converted to vitamin D3 -- would be equivalent to levels present in two medium-sized eggs or 28 grams of tuna. To convert this into active vitamin D3, the fruit would still need to be exposed to UVB light, or they could potentially be grown outdoors, something the researchers plan to test in upcoming field trials. The research was published in Nature Plants. "Unlike GMOs, the tomato plants do not contain genes from other organisms and could theoretically have been created through selective breeding -- albeit much more slowly," notes the Guardian. Therefore, they could be allowed under a proposed genetic technology (precision breeding) bill aimed to allow gene-edited plants to be treated differently to genetically modified organisms (GMOs).

The BBC reports on "the next generation of genetic modification technology" — which goes beyond simply introducing a "lab-tweaked gene" into an organism. Instead it introduces a "gene drive" — a lab-tweaked gene "that targets and removes a specific natural gene." if an animal (parent A) that contains a gene drive mates with one that doesn't (parent B), then in the forming embryo that starts to combine their genetic material, parent A's gene drive immediately gets to work. It recognises the natural gene version of itself in the opposite chromosome from parent B, and destroys it, by cutting it out of the DNA chain. Parent B's chromosome then repairs itself — but does so, by copying parent A's gene drive. So, the embryo, and the resulting offspring, are all but guaranteed to have the gene drive, rather than a 50% chance with standard GM — because an embryo takes half its genes from each parent.

Gene drives are created by adding something called Crispr, a programmable DNA sequence, to a gene. This tells it to target the natural version of itself in the DNA of the other parent in the new embryo. The gene drive also contains an enzyme that does the actual cutting.

It is hoped that gene drives can be used to greatly reduce the numbers of malarial mosquitos, and other pests or invasive species.... One organisation at the forefront of this is Target Malaria, which has developed gene drives that stop mosquitos from producing female offspring. This is important for two reasons — only the females bite, and without females, mosquito numbers will plummet. The core aim is to greatly reduce the number of people who die from malaria — of which there were sadly 627,000 in 2020, according to the World Health Organization. It could also slash the economic impact of the disease. With 241 million cases in 2020, mostly in Africa, malaria is estimated to cost the continent $12bn (£9.7bn) in reduced economic output every year....

One of the world's pioneering developers of gene drives is US biologist Kevin Esvelt, an assistant professor at Massachusetts Institute of Technology. He first came up with the technology back in 2013.... Prof Esvelt adds that this technology is being provided by something called "daisy chain". This is where a gene drive is designed to become inert after a few generations. Or halving its spread every generation until it eventually stops. Using this technology he says it is possible to control and isolate the spread of gene drives. "A town could release GM organisms with its boundaries to alter the local population [of a particular organism] while minimally affecting the town next door," he says.
The technology has not been authorized for use "in the wild," the article points out. But there are currently no bans on laboratories researching it.

Bill Gates shares a statistic about the COVID-19 pandemic. "If we'd been able to stop it within 100 days, we would've saved over 98% of the lives." "Viruses spread exponentially, and so if you get in there when the infection rate is fairly small, you can actually stop the spread."
In a new TED talk, Gates argues that we did learn a lot from this pandemic — enough to build a prevention system for next time. "Covid 19 can be the last pandemic if we take the right steps." But the answer isn't vaccines. "We also need vaccines, but we want to stop the outbreak before we have to do a global vaccination campaign." And then Gates points out that currently it could take months to get resources to a low-income country experiencing an outbreak.

Read on for Slashdot's report on Gates' proposed solution — and how he feels about his own prominence in anti-vaccine misinformation.

The Covid-19 pandemic "would look very different if scientists had been able to develop a treatment sooner," writes Bill Gates, in a guest essay Friday in the New York Times. This ultimately would've reduced fatalities — "and it may have been harder for myths and misinformation to spread the way they did."

But note that Gates said "treatment" — not vaccine. Gates believes most people in the public health community had expected an effective treatment would appear before vaccines became available. Unfortunately, that's not what happened. Safe, effective Covid vaccines were available within a year — a historic feat — but treatments that could keep large numbers of people out of the hospital were surprisingly slow out of the gate....

In late 2021, a few of their efforts paid off — not as soon as would have been ideal, but still in time to have a big impact. Merck and its partners developed an antiviral called molnupiravir, which was shown to significantly reduce the risk of hospitalization or death for people at high risk. Soon after, another oral antiviral, Paxlovid, made by Pfizer, also proved to be very effective, reducing the risk of severe illness or death by nearly 90 percent among high-risk, unvaccinated adults. These drugs are useful tools for combating the pandemic, but they arrived much later than they should have and, for many, they are still difficult to access....

It's a mistake to think of vaccines as the star of the show and therapeutics as the opening act you would just as soon skip. We're lucky that scientists made Covid vaccines as quickly as they did — if they hadn't, the death toll would be far worse. But in the event of another pandemic, even if the world is able to develop a vaccine for a new pathogen in 100 days, it will still take a long time to get the vaccine to most of the population.... With good therapeutics, the risk of severe illness and death could drop significantly, and countries could decide to loosen restrictions on schools and businesses, reducing the disruption to education and the economy. What's more, imagine how people's lives would change if we're able to take the next step by linking testing and treatment. Anyone with early symptoms that might indicate Covid (or any other viral disease) could walk into a pharmacy or clinic anywhere in the world, get tested and, if positive for the virus, walk out with antivirals to take at home....

In short, although therapeutics didn't rescue us from Covid, they hold a lot of promise for saving lives and preventing future outbreaks from crippling health systems. But to make the most of that promise, the world needs to invest in the research and systems we'll need to find treatments much faster. That's why my foundation has supported a therapeutics accelerator at Duke University, but broader initiatives will be necessary to make lasting change. This will require substantial investment to bring together academia, industry and the latest software tools. But if we succeed, the next time the world faces an outbreak, we'll save millions more lives.
Gates offers several specific recommendations — including "investing in large libraries of drug compounds that researchers can quickly scan to see whether existing therapies work against new pathogens." And... With advances in artificial intelligence and machine learning, it's now possible to use computers to identify weak spots on pathogens that we already know about, and we'll be able to do the same when new pathogens arise. These technologies are also speeding up the search for new compounds that will attack those weak spots. With adequate funding, various groups could take the most promising new compounds through Phase 1 studies even before there's an epidemic, or at least have several leads that can be turned into a product quickly once we know what the target looks like.

The U.S. government recently gave California approval to release millions of genetically engineered mosquitoes bred by British biotech company Oxitec, reports the Los Angeles Times: Oxitec, a private company, says its genetically modified bugs could help save half the world's population from the invasive Aedes aegypti mosquito, which can spread diseases such as yellow fever, chikungunya and dengue to humans. Female offspring produced by these modified insects will die, according to Oxitec's plan, causing the population to collapse. "Precise. Environmentally sustainable. Non-toxic," the company says on its website of its product trademarked as the "Friendly" mosquito.

Scientists independent from the company and critical of the proposal say not so fast. They say unleashing the experimental creatures into nature has risks that haven't yet been fully studied, including possible harm to other species or unexpectedly making the local mosquito population harder to control....

Nathan Rose, Oxitec's head of regulatory affairs, noted that the company found its mosquito reduced the population in a Brazilian neighborhood by 95% in just 13 weeks. So far, Oxitec has released little of its data from that experiment or from a more recent release in the Florida Keys. It hasn't yet published any of those results in a peer-reviewed scientific journal — publications that scientists expect when evaluating a new drug or technology....

Among scientists' concerns is that releasing the genetically modified mosquitoes into neighborhoods could create hybrids that are hardier and more dangerous to humans than the state's current population.... An EPA spokesperson said regulators expected that mosquitoes with the corporate genes "would disappear from the environment within 10 generations of mosquitoes because they are not able to reproduce as successfully as local populations." To prove this, the agency has required Oxitec to monitor neighborhoods for mosquitoes that have DNA from its engineered insects until none have been found for at least 10 consecutive weeks.
One bioethicist at Harvard Medical School told the Times that California has never had a case where this breed of mosquitos had actually transmitted disease, and argued that America's Environmental Protection Agency was "not a modern enough regulatory structure for a very modern and complicated technology."

After the U.S. government's approval, the genetically-engineered mosquitors still face several more months of scientific evaluation from California's Department of Pesticide Regulation.

Thanks to long-time Slashdot reader schwit1 for sharing the link

An anonymous reader quotes a report from the Guardian: Scientists have developed a blood test that can predict whether someone is at high risk of a heart attack, stroke, heart failure or dying from one of these conditions within the next four years. The test, which relies of measurements of proteins in the blood, has roughly twice the accuracy of existing risk scores. It could enable doctors to determine whether patients' existing medications are working or whether they need additional drugs to reduce their risk. It could also be used to hasten the development of new cardiovascular drugs by providing a faster means of assessing whether drug candidates are working during clinical trials. The test is already being used in four healthcare systems within the US and [...] it could be introduced to the UK in the near future.

[Researchers] used machine learning to analyze 5,000 proteins in blood plasma samples from 22,849 people and identify a signature of 27 proteins that could predict the four-year likelihood of heart attack, stroke, heart failure or death. When validated in 11,609 individuals, they found their model was roughly twice as good as existing risk scores, which use a person's age, sex, race, medical history, cholesterol and blood pressure to assess their likelihood of having a cardiovascular event. The results were published in Science Translational Medicine. Importantly, the test can also accurately assess risk in people who have previously had a heart attack or stroke, or have additional illnesses, and are taking drugs to reduce their risk, which is where existing risk prediction scores tend to fall down.

"Researchers in the United Kingdom have developed an autonomous, snakelike robot designed to slither down human lungs into places that are difficult for medical professionals to reach," reports the Washington Post.

The tool "could improve the detection and treatment of lung cancer and other pulmonary diseases." In a medical paper released in the journal of Soft Robotics last week, scientists from the University of Leeds unveiled a new "magnetic tentacle robot," which is composed of magnetic discs and is roughly 2 millimeters thick — about double the size of a ballpoint pen tip — and less than a-tenth-of-an-inch long.

In the future, the robot's use could be expanded to help doctors better, and more thoroughly, investigate other organs, such as the human heart, kidney or pancreas, they said....

The robot is still 5 to 10 years away from showing up in a clinical setting, researchers said, but the device comes on the heels of a fleet of other robotic innovations allowing doctors the ability to better scan a patient's lungs for cancerous tissue. They are designed to ease a task doctors have long struggled with: reaching the inner recesses of the human body, for diagnostic and treatment purposes, without causing damage or using invasive procedures.... [I]ts smaller size and magnetic composition would allow it to shape-shift more easily and better navigate the intricate shape of a lung's network of airways, which can look like a tree....

Once at its desired location, the robot could ultimately have the capability to take a tissue sample or deliver a clinical treatment.... Nitish V. Thakor, a professor of biomedical engineering at Johns Hopkins University, said the autonomous robot is "very novel and interesting technology" that could become potentially useful in areas outside the lungs, most notably the heart. The device's autonomous capability is its unique factor, he said, and has the capability to change invasive surgeries. "I can imagine a future," he said, "where a full [cancer-screening] CAT scan is done of the lungs, and the surgeon sits down on a computer and lays out this navigation path of this kind of a snake robot and says: 'Go get it.' "

An anonymous reader quotes a report from New Atlas: One of the first products made using a novel animal-free egg white is now available in the United States. The unique macarons are the first to be made with an egg white protein that comes from engineered yeast, designed to be indistinguishable from what is found in chicken eggs. The Every Company, founded in 2014 under the name Clara Foods, is one of several food technology companies working to create real animal-free proteins using a method called precision fermentation. The idea behind the process is to break down certain animal products, such as milk and eggs, to their molecular components and then use microorganisms to produce those components. Earlier this year the first cow-free dairy milk using this method hit supermarket shelves in the United States. That product was created using whey proteins from engineered fungus, while other companies are working on similar dairy products using engineered yeast to produce the desired milk proteins.

The Every Company has spent the last few years focusing on using the same technique to produce chicken-free egg whites, working with engineered yeast to produce proteins found in egg whites. The company has not disclosed the specific combination of proteins used to create its final egg white product, however it is likely ovalbumin -- the primary protein component in egg whites -- plays a strong role in the recipe. Arturo Elizondo, CEO of Every Company, said the new egg white product functions exactly like a chicken-derived egg white. It whips, aerates and bakes in ways identical to traditional egg whites, and the company has teamed up with San Francisco-based bakery Chantal Guillon to launch the product in a line of iconic French macarons. The chicken-free egg white is the third animal-free product created by the Every Company. Its first fully commercialized product was an animal-free pepsin, launched in early 2021.

On Saturday CNBC published a remarkable headline. "Stem cells may finally offer a cure for Type 1 diabetes." There are 537 million people around the world living with diabetes. And that number is growing.... But over the past 20 years, significant advancements in stem cell research and therapies have revealed promising methods of creating new insulin-making cells, which are needed to cure Type 1 diabetes. Biotech company Vertex Pharmaceuticals recently began a clinical trial where it plans to treat 17 participants who have Type 1 diabetes with new insulin-making cells derived from stem cells. The first patient in the trial, Brian Shelton, has had positive results. After 150 days, Shelton was able to reduce the amount of insulin he injects by 92%.

Other global companies are also working to cure diabetes, such as ViaCyte, CRISPR, and Novo Nordisk, one of the biggest insulin manufacturers in the world.
In CNBC's 20-minute video, a VP/disease area executive from Vertex Pharmaceuticals explains that diabetes is "one of the few diseases where a single cell type is destroyed or missing" — the pancreas cell that produces insulin. So they're exploring "the idea that if you could create those cells and replace them, you can really address the underlying causal biology of the disease directly."

CNBC also spoke to Brian Shelton, the trial's first patient, who's been a Type 1 diabetic for 44 years, and whose pancreas suddenly started producing insulin again. "Now my body does it all on its own," Shelton says. The news was especially surprising, CNBC reports, because "as the first person in the trial, Shelton received only half of the anticipated dose to ensure it was safe."

One researcher they spoke to even predicts that biological solutions will compete with "ongoing efforts to use nanotechnology to miniaturize all the hardware necessary to do this," and that within the next 3 to 5 years patients will finally have the option of "something that is really Cadillac." And Aaron Kowalski, CEO of the nonprofit Juvenile Diabetes Research Foundation, tells CNBC, "I am fully convinced that I will walk away from my insulin pump and continuous glucose monitor in my lifetime, and I would be disappointed if it wasn't in this decade."

CNBC's report concludes, "For diabetics who want a cure that requires no additional treatment, it may no longer be a question of if, but a matter of when."

The U.S. government's "dithering" has left the country "well behind" China in the race to build out 5G technology, former Google CEO Eric Schmidt said, as he urged Washington to step up investment in the next-generation internet technology. From a report: Writing in an op-ed in the Wall Street Journal, Schmidt and Graham Allison, a professor of government at Harvard, said that America is "far behind in almost every dimension of 5G while other nations -- including China -- race ahead." The authors urged the Biden administration to make 5G a "national priority." Otherwise, they said, "China will own the 5G future." 5G refers to next-generation wireless internet that promises super-fast download speeds. But it could also form the basis for industrial and military applications and form a way for devices to communicate with each other. That's why it's seen as a critical technology and one of the reasons China is moving quickly with its own 5G rollout and future applications.

New submitter blackprint writes: The City of Austin released a memo saying that Samsung released as much as 763,000 gallons of sulfuric acid waste into a Northeast Austin creek over a period as long as 106 days. They confirmed the leak has stopped, but no fish or macro invertebrates survived in the impacted area. They don't know if there are any long-term impacts, but pH levels in the area have returned close to normal. According to the memo, "Public access to this area is limited, and there are no nearby parks."

They have not stated the cause of the spill. "Spill investigators and scientists took a look at the area Jan. 18-19 and saw iron staining in the tributary channel consistent with a low pH environment," reports local news station KXAN, citing the memo. "WPD says it was in this tributary stretch from the Samsung plant to the main branch of Harris Branch Creek that WPD staff found no surviving aquatic life, including fish."

An anonymous reader quotes a report from Motherboard: Dr. Garry Nolan is a Professor of Pathology at Stanford University. His research ranges from cancer to systems immunology. Dr. Nolan has also spent the last ten years working with a number of individuals analyzing materials from alleged Unidentified Aerial Phenomenon. His robust resume -- 300 research articles, 40 US patents, founding of eight biotech companies, and honored as one of Stanford's top 25 inventors -- makes him, easily, one of the most accomplished scientists publicly studying UAPs. Motherboard sat down with Garry to discuss his work. It has been edited for length and clarity. Motherboard's Thobey Campion starts by asking Dr. Nolan how he first became interested in UAPs. I've always been an avid reader of science fiction, so it was natural at some point that when YouTube videos about UFOs began to make the rounds I might watch a few. I noticed that this guy at the time, Steven Greer, had claimed that a little skeleton might be an alien. I remember thinking, 'Oh, I can prove or disprove that.' And so I reached out to him. I eventually showed that it wasn't an alien, it was human. We explain a fair amount about why it looked the way it did. It had a number of mutations in skeletal genes that could potentially explain the biology. The UFO community didn't like me saying that. But you know, the truth is in the science. So, I had no problem just stating the facts. We published a paper and it ended up going worldwide. It was on the front page of just about every major newspaper. What's more appealing or clickbait than 'Stanford professor sequences alien baby'?

That ended up bringing me to the attention of some people associated with the CIA and some aeronautics corporations. At the time, they had been investigating a number of cases of pilots who'd gotten close to supposed UAPs and the fields generated by them, as was claimed by the people who showed up at my office unannounced one day. There was enough drama around the Atacama skeleton that I had basically decided to forswear all continued involvement in this area. Then these guys showed up and said, 'We need you to help us with this because we want to do blood analysis and everybody says that you've got the best blood analysis instrumentation on the planet.' Then they started showing the MRIs of some of these pilots and ground personnel and intelligence agents who had been damaged. The MRIs were clear. You didn't even have to be an MD to see that there was a problem. Some of their brains were horribly, horribly damaged. And so that's what kind of got me involved. Dr. Nolan expanded on the MRIs, saying they resemble the white matter disease, or scarring, that occurs with multiple sclerosis, with the symptomology that's basically identical to what's now called Havana syndrome. "That still left individuals who had seen UAPs. They didn't have Havana syndrome. They had a smorgasbord of other symptoms."

When asked if there's anything man-made that might have this impact on the brain, Dr. Nolan said: "The only thing I can imagine is you're standing next to an electric transformer that's emitting so much energy that you're basically getting burned inside your body."

As for the UAP fragments, Dr. Nolan said some of the objects are "nondescript," and just "lumps of metal" with nothing particularly unusual about them "except that everywhere you look in the metal, the composition is different, which is odd." He added: "The common thing about all the materials that I've looked at so far, and there's about a dozen, is that almost none of them are uniform. They're all these hodgepodge mixtures. Each individual case will be composed of a similar set of elements, but they will be inhomogeneous."

Of the 10 or 12 UAP fragments he's looked at, "two seem to be not playing by our rules," he says. "That doesn't mean that they're levitating, on my desk or anything, it just means that they have altered isotope ratios."

You can read the full Q&A here.

Three years ago Strella Biotechnology launched to "try to reduce waste in the U.S. food system — a problem that by some estimates creates as much emissions as 33 million passenger vehicles," reports the Washington Post. Alternate URL here and here.)

And today the founder's warehouse-monitoring device — about half the size of a shoebox — watches over about 15% of all the apples grown in America: Already, agriculture contributes more to greenhouse gas emissions than the total of all the cars, planes, trains and trucks in the world. The pressure to grow more food is leading to deforestation in the Amazon, the drying up of rivers and a greater demand for fossil fuel-based fertilizer. Anything that can be done to reduce waste and increase the productivity of existing agricultural land is a big win for the climate. [Strella CEO and founder] Sizov, 24, wants to eliminate food waste one fruit at a time...

Sizov chanced upon a website that described the climate impact of food waste — up to 4% of U.S. greenhouse gas emissions, according to analyses from ReFed, a nonprofit organization that works to reduce food waste... The problem will only intensify as the global population grows, experts say. By 2050, the United Nations expects there will be another 2 billion mouths to feed around the world, an increase of more than 25% in just three decades. And as countries such as China and India grow richer, their populations are gradually changing their eating habits: more meat, more eggs — and a bigger carbon footprint tied to raising all of those animals and clearing off land to grow more food. "If you reduce food loss and waste by 50%, you can save a lot of production emissions, but you can also avoid a heck of a lot of deforestation," said Tim Searchinger, a senior research scholar at Princeton University's Center for Policy Research on Energy and the Environment. Searchinger explained that after accounting for the fact that an acre of farmland could otherwise be an acre of forest, the carbon footprint of food skyrockets as trees soak up so much carbon dioxide.

Eliminating waste also happens to be a way to help farmers and grocery stores earn more money, since the more efficiently food makes it to consumers, the more cash ends up with the people who've done the selling... [T]hat's where Strella's sensors come in. They monitor ethylene, a gas key to the ripening of fruits and vegetables. Apples accelerate their production of ethylene as they grow sweeter inside the storerooms. Once they're ready, the gas levels off, telling Strella's monitors that they're ready to be sent to supermarkets. Wait too long and the apples turn brown or grow mealy. If producers are lucky, they can try to break even by turning those apples into juice or applesauce. If they're unlucky, the overripe apples end up in compost or landfills.
Ultimately one out of every five apples doesn't make it from the warehouse to the supermarket, the Post points out (while some others lose their crunch). So Sizov hopes their waste-reducing technology will catch on because it's also a way to reduce business losses. "There's a direct alignment of a sustainable goal with a profitability incentive."

Months-long silences. Mysterious rejections. Here's what's behind the shortages of a critical tool for ending the pandemic. ProPublica: A few weeks ago, a ProPublica reporter decided to test his kids for COVID-19. They had the sniffles, and with a grandparent set to visit he wanted to minimize the risk that they were infectious. This was the problem that quick, cheap COVID-19 tests were supposed to help fix. No need to go to a clinic or wait days for results. Just pick up a pack of tests at a local pharmacy whenever you want, swab your nose and learn within 15 minutes if you're likely to pass the virus along. So the ProPublican went to his neighborhood CVS, hoping to buy the required pack of two for $23.99. They were out of stock. Then he went to Rite Aid. They didn't have the tests either. Then Walgreens, then another CVS. All out of stock. The only supplier with a few tests to offer was his sister, who happened to have a few tucked away. It's a familiar experience for many Americans. But not for people in Britain, who get free rapid tests delivered to their homes on demand. Or France, Germany or Belgium, where at-home tests are ubiquitous and as cheap as a decent cappuccino. So why are at-home tests still so pricey and hard to find in the United States?

The answer appears to be a confounding combination of overzealous regulation and anemic government support -- issues that have characterized America's testing response from the beginning of the pandemic. Companies trying to get the Food and Drug Administration's approval for rapid COVID-19 tests describe an arbitrary, opaque process that meanders on, sometimes long after their products have been approved in other countries that prioritize accessibility and affordability over perfect accuracy. After the FDA put out a call for more rapid tests in the summer of 2020, Los Angeles-based biotech company WHPM, Inc. began working on one. They did a peer-reviewed trial following the agency's directions, then submitted the results this past March. In late May, WHPM head of international sales Chris Patterson said, the company got a confusing email from its FDA reviewer asking for information that had in fact already been provided. WHPM responded within two days. Months passed. In September, after a bit more back and forth, the FDA wrote to say it had identified other deficiencies, and wouldn't review the rest of the application. Even if WHPM fixed the issues, the application would be "deprioritized," or moved to the back of the line.

"We spent our own million dollars developing this thing, at their encouragement, and then they just treat you like a criminal," said Patterson. Meanwhile, the WHPM rapid test has been approved in Mexico and the European Union, where the company has received large orders. An FDA scientist who vetted COVID-19 test applications told ProPublica he became so frustrated by delays that he quit the agency earlier this year. "They're neither denying the bad ones or approving the good ones," he said, asking to remain anonymous because his current work requires dealing with the agency. FDA officials said they simply want to ensure that rapid tests detect even low levels of the virus, since false negative test results could cause people to unwittingly spread the disease. They blame the test shortages on an absence of the kind of sustained public funding that European governments have provided. Without it, manufacturers have lacked confidence that going through the FDA's process would be financially worth the trouble.

Twenty-somethings rolling their eyes at the habits of their elders is a longstanding trend, but many employers said there's a new boldness in the way Gen Z dictates taste. From a report: At a retail business based in New York, managers were distressed to encounter young employees who wanted paid time off when coping with anxiety or period cramps. At a supplement company, a Gen Z worker questioned why she would be expected to clock in for a standard eight-hour day when she might get through her to-do list by the afternoon. At a biotech venture, entry-level staff members delegated tasks to the founder. And spanning sectors and start-ups, the youngest members of the work force have demanded what they see as a long overdue shift away from corporate neutrality toward a more open expression of values, whether through executives displaying their pronouns on Slack or putting out statements in support of the protests for Black Lives Matter. "These younger generations are cracking the code and they're like, 'Hey guys turns out we don't have to do it like these old people tell us we have to do it,'" said Colin Guinn, 41, co-founder of the robotics company Hangar Technology. "'We can actually do whatever we want and be just as successful.' And us old people are like, 'What is going on?'"

Twenty-somethings rolling their eyes at the habits of their elders is a trend as old as Xerox, Kodak and classic rock, but many employers said there's a new boldness in the way Gen Z dictates taste. And some members of Gen Z, defined as the 72 million people born between 1997 and 2012, or simply as anyone too young to remember Sept. 11, are quick to affirm this characterization. Ziad Ahmed, 22, founder and chief executive of the Gen Z marketing company JUV Consulting, which has lent its expertise to brands like JanSport, recalled speaking at a conference where a Gen Z woman, an entry-level employee, told him she didn't feel that her employer's marketing fully reflected her progressive values. "What is your advice for our company?" the young woman asked. "Make you a vice president," Mr. Ahmed told her. "Rather than an intern." Starting in the mid-aughts, the movement of millennials from college into the workplace prompted a flurry of advice columns about hiring members of the headstrong generation. "These young people tell you what time their yoga class is," warned a "60 Minutes" segment in 2007 called "The 'Millennials' Are Coming." Over time, those millennials became managers, and workplaces were reshaped in their image. There were #ThankGodIt'sMonday signs affixed to WeWork walls. There was the once-heralded rise of the SheEO.

Samsung has proposed a way to build brain-like computer chips by "copying and pasting" a brain's neuron wiring map onto 3D neuromorphic chips. Engadget reports: The approach would rely on a nanoelectrode array that enters a large volumes of neurons to record both where the neurons connect and the strength of those connections. You could copy that data and 'paste' it to a 3D network of solid-state memory, whether it's off-the-shelf flash storage or cutting-edge memory like resistive RAM. Each memory unit would have a conductance that reflects the strength of each neuron connection in the map. The result would be an effective return to "reverse engineering the brain" like scientists originally wanted, Samsung said.

The move could serve as a 'shortcut' to artificial intelligence systems that behave like real brains, including the flexibility to learn new concepts and adapt to changing conditions. You might even see fully autonomous machines with true cognition, according to the researchers.
"Envisioned by the leading engineers and scholars from Samsung and Harvard University, the insight was published as a Perspective paper, titled 'Neuromorphic electronics based on copying and pasting the brain'..." Samsung said in a statement.

In short, they're proposing a method that "directly downloads the brain's neuronal connection map onto the memory chip."

Federal prosecutors allege that Elizabeth Holmes and the No. 2 at Theranos, Ramesh "Sunny" Balwani, "broke the law by deceiving investors about how well the business was doing and the capabilities of its testing machines, in addition to allegedly providing false or flawed test results to patients," reports NPR.

But they add that in Silicon Valley, the trial has launched this debate. "Since Holmes was following a playbook used by dozens of tech CEOs, why is she the only one to face prosecution when a company becomes engulfed in a scandal?" To Ellen Pao, the former CEO of Reddit, who is a vocal critic of gender discrimination in tech, sexism is partially to blame. "When you see which CEOs get to continue to wreak havoc on consumers and the market, it's people who look like the venture capitalists, who are mostly white men," Pao said. She points to Adam Neumann, who drove WeWork into the ground; former Uber CEO Travis Kalanick, who resigned after a sexual harassment scandal; and Juul's Kevin Burns, who stepped down amid questions over the company's role in stoking the youth vaping epidemic. There were lawsuits, settlements and more fallout — but notably, Pao points out, no criminal prosecutions.

"That all these people continue to lead their lives and not be held accountable for all the harm that they've caused, it does send a message," she said.

Former prosecutors who have tried white-collar crime say there are several reasons why Holmes stands out among disgraced tech CEOs. First, the allegedly fraudulent behavior was egregious: Holmes told the world she had a miracle machine that would upend laboratory science. Prosecutors say, compared with her claims, the technology barely did anything at all. Mark MacDougall, a former federal prosecutor who focused on fraud cases in the U.S. Justice Department, said Theranos' being a biotech company raised the stakes. "It allows the government to contend, with some evidence, that the health of private citizens, the health of innocent people, was put at risk," MacDougall said. Another reason Holmes was charged, according to former prosecutors, was that the government says it obtained evidence that she acted intentionally, which can be difficult to establish in fraud cases.
Prosecutors now plan to show Holmes "knowingly and intentionally" defrauded investors and patients, "something her defense team says is false," the article points out. "Proving that Holmes is guilty will turn on demonstrating her intent, since exaggerating a product's potential, missing financial forecasts and running a secretive company do not constitute federal crimes."

Pao's argument is that Holmes "was encouraged by the high-risk, high-reward culture of venture capital. That said, Pao said she is not defending Holmes, saying her behavior warranted prosecution."

"At the same time, Pao wants a broader discussion in Silicon Valley about why other CEOs accused of wrongdoing have not faced criminal consequences."

AltMachine shares a report from Phys.Org: Chinese scientists recently reported a de novo route for artificial starch synthesis from carbon dioxide (CO2) for the first time. Relevant results were published in Science on Sept. 24. The new route makes it possible to produce starch, a major component of grains, by industrial manufacturing instead of traditional agricultural planting and opens up a new technical route for synthesizing complex molecules from CO2. The artificial route can produce starch from CO2 with an efficiency 8.5-fold higher than starch biosynthesis in maize, suggesting a big step towards going beyond nature. It provides a new scientific basis for creating biological systems with unprecedented functions. "If the overall cost of the process can be reduced to a level economically comparable with agricultural planting in the future, it is expected to save more than 90% of cultivated land and freshwater resources," said MA Yanhe, corresponding author of the study. In addition, it would also help to avoid the negative environmental impact of using pesticides and fertilizers, improve human food security, facilitate a carbon-neutral bioeconomy, and eventually promote the formation of a sustainable bio-based society.